Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia

Research output: Contribution to journalJournal articlepeer-review

Standard

Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. / Abdissa, Alemseged; Yilma, Daniel; Fonager, Jannik; Audelin, Anne M; Christensen, Lone H; Olsen, Mette Frahm; Tesfaye, Markos; Kæstel, Pernille; Girma, Tsinuel; Aseffa, Abraham; Friis, Henrik; Pedersen, Court; Andersen, Åse B.

In: B M C Infectious Diseases, Vol. 14, 181, 2014.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Abdissa, A, Yilma, D, Fonager, J, Audelin, AM, Christensen, LH, Olsen, MF, Tesfaye, M, Kæstel, P, Girma, T, Aseffa, A, Friis, H, Pedersen, C & Andersen, ÅB 2014, 'Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia', B M C Infectious Diseases, vol. 14, 181. https://doi.org/10.1186/1471-2334-14-181

APA

Abdissa, A., Yilma, D., Fonager, J., Audelin, A. M., Christensen, L. H., Olsen, M. F., Tesfaye, M., Kæstel, P., Girma, T., Aseffa, A., Friis, H., Pedersen, C., & Andersen, Å. B. (2014). Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. B M C Infectious Diseases, 14, [181]. https://doi.org/10.1186/1471-2334-14-181

Vancouver

Abdissa A, Yilma D, Fonager J, Audelin AM, Christensen LH, Olsen MF et al. Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. B M C Infectious Diseases. 2014;14. 181. https://doi.org/10.1186/1471-2334-14-181

Author

Abdissa, Alemseged ; Yilma, Daniel ; Fonager, Jannik ; Audelin, Anne M ; Christensen, Lone H ; Olsen, Mette Frahm ; Tesfaye, Markos ; Kæstel, Pernille ; Girma, Tsinuel ; Aseffa, Abraham ; Friis, Henrik ; Pedersen, Court ; Andersen, Åse B. / Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. In: B M C Infectious Diseases. 2014 ; Vol. 14.

Bibtex

@article{74d14bf5edd948ed8b96c160f1f353b9,
title = "Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia",
abstract = "BACKGROUND: The ongoing scale-up of antiretroviral therapy (ART) in sub-Saharan Africa has prompted the interest in surveillance of transmitted and acquired HIV drug resistance. Resistance data on virological failure and mutations in HIV infected populations initiating treatment in sub-Saharan Africa is sparse.METHODS: HIV viral load (VL) and resistance mutations pre-ART and after 6 months were determined in a prospective cohort study of ART-na{\"i}ve HIV patients initiating first-line therapy in Jimma, Ethiopia. VL measurements were done at baseline and after 3 and 6 months. Genotypic HIV drug resistance (HIVDR) was performed on patients exhibiting virological failure (>1000 copies/mL at 6 months) or slow virological response (>5000 copies/mL at 3 months and <1000 copies/mL at 6 months).RESULTS: Two hundred sixty five patients had VL data available at baseline and at 6 months. Virological failure was observed among 14 (5.3%) participants out of 265 patients. Twelve samples were genotyped and six had HIV drug resistance (HIVDR) mutations at baseline. Among virological failures, 9/11 (81.8%) harbored one or more HIVDR mutations at 6 months. The most frequent mutations were K103N and M184VI.CONCLUSIONS: Our data confirm that the currently recommended first-line ART regimen is efficient in the vast majority of individuals initiating therapy in Jimma, Ethiopia eight years after the introduction of ART. However, the documented occurrence of transmitted resistance and accumulation of acquired HIVDR mutations among failing patients justify increased vigilance by improving the availability and systematic use of VL testing to monitor ART response, and underlines the need for rapid, inexpensive tests to identify the most common drug resistance mutations.",
author = "Alemseged Abdissa and Daniel Yilma and Jannik Fonager and Audelin, {Anne M} and Christensen, {Lone H} and Olsen, {Mette Frahm} and Markos Tesfaye and Pernille K{\ae}stel and Tsinuel Girma and Abraham Aseffa and Henrik Friis and Court Pedersen and Andersen, {{\AA}se B}",
note = "OA",
year = "2014",
doi = "10.1186/1471-2334-14-181",
language = "English",
volume = "14",
journal = "B M C Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia

AU - Abdissa, Alemseged

AU - Yilma, Daniel

AU - Fonager, Jannik

AU - Audelin, Anne M

AU - Christensen, Lone H

AU - Olsen, Mette Frahm

AU - Tesfaye, Markos

AU - Kæstel, Pernille

AU - Girma, Tsinuel

AU - Aseffa, Abraham

AU - Friis, Henrik

AU - Pedersen, Court

AU - Andersen, Åse B

N1 - OA

PY - 2014

Y1 - 2014

N2 - BACKGROUND: The ongoing scale-up of antiretroviral therapy (ART) in sub-Saharan Africa has prompted the interest in surveillance of transmitted and acquired HIV drug resistance. Resistance data on virological failure and mutations in HIV infected populations initiating treatment in sub-Saharan Africa is sparse.METHODS: HIV viral load (VL) and resistance mutations pre-ART and after 6 months were determined in a prospective cohort study of ART-naïve HIV patients initiating first-line therapy in Jimma, Ethiopia. VL measurements were done at baseline and after 3 and 6 months. Genotypic HIV drug resistance (HIVDR) was performed on patients exhibiting virological failure (>1000 copies/mL at 6 months) or slow virological response (>5000 copies/mL at 3 months and <1000 copies/mL at 6 months).RESULTS: Two hundred sixty five patients had VL data available at baseline and at 6 months. Virological failure was observed among 14 (5.3%) participants out of 265 patients. Twelve samples were genotyped and six had HIV drug resistance (HIVDR) mutations at baseline. Among virological failures, 9/11 (81.8%) harbored one or more HIVDR mutations at 6 months. The most frequent mutations were K103N and M184VI.CONCLUSIONS: Our data confirm that the currently recommended first-line ART regimen is efficient in the vast majority of individuals initiating therapy in Jimma, Ethiopia eight years after the introduction of ART. However, the documented occurrence of transmitted resistance and accumulation of acquired HIVDR mutations among failing patients justify increased vigilance by improving the availability and systematic use of VL testing to monitor ART response, and underlines the need for rapid, inexpensive tests to identify the most common drug resistance mutations.

AB - BACKGROUND: The ongoing scale-up of antiretroviral therapy (ART) in sub-Saharan Africa has prompted the interest in surveillance of transmitted and acquired HIV drug resistance. Resistance data on virological failure and mutations in HIV infected populations initiating treatment in sub-Saharan Africa is sparse.METHODS: HIV viral load (VL) and resistance mutations pre-ART and after 6 months were determined in a prospective cohort study of ART-naïve HIV patients initiating first-line therapy in Jimma, Ethiopia. VL measurements were done at baseline and after 3 and 6 months. Genotypic HIV drug resistance (HIVDR) was performed on patients exhibiting virological failure (>1000 copies/mL at 6 months) or slow virological response (>5000 copies/mL at 3 months and <1000 copies/mL at 6 months).RESULTS: Two hundred sixty five patients had VL data available at baseline and at 6 months. Virological failure was observed among 14 (5.3%) participants out of 265 patients. Twelve samples were genotyped and six had HIV drug resistance (HIVDR) mutations at baseline. Among virological failures, 9/11 (81.8%) harbored one or more HIVDR mutations at 6 months. The most frequent mutations were K103N and M184VI.CONCLUSIONS: Our data confirm that the currently recommended first-line ART regimen is efficient in the vast majority of individuals initiating therapy in Jimma, Ethiopia eight years after the introduction of ART. However, the documented occurrence of transmitted resistance and accumulation of acquired HIVDR mutations among failing patients justify increased vigilance by improving the availability and systematic use of VL testing to monitor ART response, and underlines the need for rapid, inexpensive tests to identify the most common drug resistance mutations.

U2 - 10.1186/1471-2334-14-181

DO - 10.1186/1471-2334-14-181

M3 - Journal article

C2 - 24708645

VL - 14

JO - B M C Infectious Diseases

JF - B M C Infectious Diseases

SN - 1471-2334

M1 - 181

ER -

ID: 119649152